MAK Capital Tells Evotec to List US Unit Worth Over €1 billion

Activist investor MAK Capital has publicly urged German biotech firm Evotec SE to list its U.S.-based Just – Evotec Biologics unit, estimating its value to exceed €1 billion. This push comes as MAK, a significant shareholder, believes the current market valuation of Evotec does not adequately reflect the potential of its diverse operations, particularly its advanced biologics manufacturing arm. A separate listing could provide clearer financial visibility for Just – Evotec Biologics, allowing it to attract dedicated capital and investor focus aligned with its unique growth trajectory. For investors, this development signals a potential strategic realignment within Evotec. By spinning off or separately listing its U.S. biologics unit, Evotec could streamline its core drug discovery and development services, allowing each segment to pursue distinct growth strategies and potentially achieve higher valuations. The move could also provide existing Evotec shareholders with direct exposure to the high-growth biologics manufacturing sector, which is increasingly vital in the pharmaceutical landscape, without the complexities of its broader portfolio. The market's immediate reaction will hinge on Evotec's board response to MAK Capital's demands. Investors will be closely watching for any official statements or strategic reviews that could indicate a willingness to explore a separate listing. A positive indication could boost Evotec's stock, as investors anticipate the unlocking of shareholder value and a more focused business model. Conversely, resistance could lead to continued activist pressure and market uncertainty surrounding the company’s future direction.